Literature DB >> 9272950

Genetically engineered mice demonstrate that adenosine deaminase is essential for early postimplantation development.

M R Blackburn1, T B Knudsen, R E Kellems.   

Abstract

Adenosine deaminase (ADA) is an essential enzyme of purine metabolism that is enriched at the maternal-fetal interface of mice throughout postimplantation development. During early postimplantation stages Ada is highly expressed in both maternally derived decidual cells and zygotically derived trophoblast cells. For the current study we utilized genetically modified mice to delineate the relative contribution and importance of decidual and trophoblast ADA at the maternal-fetal interface. In females genetically engineered to lack decidual ADA a striking pattern of expression was revealed in giant trophoblast cells that surround the early postimplantation embryo. Embryos within gestation sites lacking both decidual and trophoblast ADA died during the early postimplantation period, whereas expression in trophoblast cells alone was sufficient for survival through this period. Severe disturbances in purine metabolism were observed in gestation sites lacking decidual ADA, including the accumulation of the potentially toxic ADA substrates adenosine and 2'-deoxyadenosine. These experiments provide genetic evidence that Ada expression at the maternal-fetal interface is essential for early postimplantation development in mice.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9272950     DOI: 10.1242/dev.124.16.3089

Source DB:  PubMed          Journal:  Development        ISSN: 0950-1991            Impact factor:   6.868


  3 in total

1.  Transcription factor gene AP-2 gamma essential for early murine development.

Authors:  Uwe Werling; Hubert Schorle
Journal:  Mol Cell Biol       Date:  2002-05       Impact factor: 4.272

2.  Radiation Response of Murine Embryonic Stem Cells.

Authors:  Christine E Hellweg; Vaibhav Shinde; Sureshkumar Perumal Srinivasan; Margit Henry; Tamara Rotshteyn; Christa Baumstark-Khan; Claudia Schmitz; Sebastian Feles; Luis F Spitta; Ruth Hemmersbach; Jürgen Hescheler; Agapios Sachinidis
Journal:  Cells       Date:  2020-07-09       Impact factor: 6.600

3.  Metabolite and thymocyte development defects in ADA-SCID mice receiving enzyme replacement therapy.

Authors:  Federico A Moretti; Giuliana Giardino; Teresa C H Attenborough; Athina Soragia Gkazi; Ben K Margetts; Giancarlo la Marca; Lynette Fairbanks; Tessa Crompton; H Bobby Gaspar
Journal:  Sci Rep       Date:  2021-12-01       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.